C
grade
Therapeutic potential and underlying mechanisms of engineered young plasma-derived exosomes in Alzheimer's disease.
Adamax · Bioactive materials · 2026 · Animal study · Preclinical
RVG-engineered exosomes from young plasma show potential in reducing AD pathology and improving cognition in mice, but human relevance remains uncertain.
Not reported in abstract.